(Q37794467)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nicola Tambasco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Barbara Picconi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Paolo Calabresi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Massimiliano Di Filippo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

27 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1106-1117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

Modification of Parkinsonism--chronic treatment with L-dopa

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Molecular mechanisms of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Molecular mechanisms underlying levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Pathogenesis of dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Dopamine-mediated regulation of corticostriatal synaptic plasticity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Synaptic plasticity, dopamine and Parkinson's disease: one step ahead

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Striatal histone modifications in models of levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Thwarting dyskinesia by targeting mTORC1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Metabotropic glutamate receptors in the basal ganglia motor circuit

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Metabotropic glutamate receptor II in the brains of Parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Serotonin and Parkinson's disease: On movement, mood, and madness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

The endocannabinoid system in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Emerging roles for endocannabinoids in long‐term synaptic plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Impact of pramipexole on the onset of levodopa-related dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Placebo influences on dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970218-0

7 January 2021

10.1016/S1474-4422(10)70218-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880751%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference